Clinical Trial Search

Phase 3 N=574 Best African American Response to Asthma Drugs

Asthma

Primary: The Primary Outcome is a Composite Measure That Uses Exacerbations, Asthma Control Days During the Last 12 of 14 Weeks of a Treatment Regimen, and Percent Predicted FEV1…

Milton S. Hershey Medical Center Results Nov 2018 2.1% serious AE View details

Phase 3 N=252 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

Crohn's Disease

Primary: Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0 — 31.6 percentage of participants

AbbVie Results Nov 2018 10.7% serious AE View details

Phase 3 N=409 A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

Primary: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 30.7; 7.4 percentage of participants — p=<0.001

Therapeutics, Inc. Results Nov 2018 0.2% serious AE View details

Phase 3 N=309 Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

Primary: Complete Clearance of Actinic Keratosis (AK) — 20.4; 2.9 percentage of participants — p=0.001

LEO Pharma Results Nov 2018 0.2% serious AE View details

Phase 3 N=917 A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

Bowel Preparation

Primary: Percentage of Subjects Classified as a Responder Defined by "Excellent" or "Good" — 87.7; 81.5 Percentage of participants — p=0.0067

Ferring Pharmaceuticals Results Nov 2018 1.7% serious AE View details

Phase 3 N=536 A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Primary: Percentage of Participants With Major Molecular Response (MMR) at Month 12 — 47.2; 36.9 percentage of participants — p=0.0100

Pfizer Results Nov 2018 31.1% serious AE View details

Phase 3 N=152 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Hemophilia A

Primary: Annualized Bleeding Rate (ABR) for Treated Bleeds — 38.2; 1.5; 1.3; 1.6 treated bleed rate per year — p=<0.0001

Hoffmann-La Roche Results Nov 2018 21.3% serious AE View details

Phase 3 N=446 Safety and Efficacy of Cariprazine in Schizophrenia

Schizophrenia

Primary: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score — -16.0; -22.8; -25.9 Units on a Scale — p=0.0029

Forest Laboratories Results Nov 2018 5.2% serious AE View details

Phase 3 N=17 Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

Primary: Efficacy of Higher Double Doses of Rituxan and of Standard Dose of Rituxan + Cyclophosphamide, Vincristine, Prednisone — 8; 7; 1; 1 Participants

Weill Medical College of Cornell University Results Nov 2018 5.9% serious AE View details

Phase 3 N=126 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

Primary: Person-time Incidence Rates (Subject Based) — 0.01; 0.03; 0.00; 0.01 participants with events/year

CSL Behring Results Nov 2018 6.8% serious AE View details

Phase 3 N=300 Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants

Malaria

Primary: Prevalence of Placental Malaria — 49; 30; 26 Participants

Grant Dorsey, M.D, Ph.D. Results Nov 2018 7.1% serious AE View details

Phase 3 N=89 Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

HIV Infection

Primary: Proportion of Participants With Treatment Failure — 0.0682; 0.0667 proportion of participants

Babafemi Taiwo Results Nov 2018 3.4% serious AE View details

Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines

Migraine

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Montefiore Medical Center Results Nov 2018 0.0% serious AE View details

Phase 3 N=284 Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

Liver Transplantation

Primary: Number of Participants With Composite Efficacy Failure of Treated Biopsy Proven Acute Rejection, Graft Loss or Death in Everolimus With Reduced Tacrolimus Group Compared…

Novartis Pharmaceuticals Results Nov 2018 55.2% serious AE View details

Phase 3 N=97 A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Primary: Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 — 40…

Hoffmann-La Roche Results Nov 2018 7.2% serious AE View details